Cell cycle and glomerular disease: A minireview

被引:71
作者
Marshall, CB [1 ]
Shankland, SJ [1 ]
机构
[1] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA
来源
NEPHRON EXPERIMENTAL NEPHROLOGY | 2006年 / 102卷 / 02期
关键词
cell cycle; kidney; glomerulus; proliferation; podocyte; mesangial cell; progressive glomerulosclerosis; hypertrophy; apoptosis;
D O I
10.1159/000088400
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Globally, glomerular diseases are a leading cause of chronic and end-stage renal disease. In the mature glomerulus, under normal conditions, glomerular cells have a low turnover rate. However, in disease, a variety of pathophysiological stimuli can lead to disturbances in glomerular cell biology, including toxins, immune-mediated stresses, metabolic derangements, drugs, infections, hemodynamic changes, growth factors, and cytokines. Not only does the form of injury govern the histologic and clinical manifestations of disease, but also the nature of the response to injury. This response to injury is largely cell-type specific, and the glomerulus represents a rare microcosm of the larger organism in which one can study the cellular responses of three very distinct cell types: mesangial cells, visceral epithelial cells or podocytes, and endothelial cells. These cells can undergo several cell fates in response to injury, including proliferation, de-differentiation, hypertrophy, senescence, apoptosis, or necrosis. The regulation of these responses occurs at the level of the cell cycle, coordinated by positive regulators, cyclins and cyclin-dependent kinases, and negative regulators, cyclin-dependent kinase inhibitors. There is now a large body of literature confirming the importance of cell cycle regulatory proteins in the glomerular cellular response to injury. The recent advances in cell cycle biology in diseases of the mesangial cell and the podocyte are the focus of this minireview. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:39 / 48
页数:10
相关论文
共 30 条
[1]
The cyclin kinase inhibitor p21WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy [J].
Al-Douahji, M ;
Brugarolas, J ;
Brown, PAJ ;
Stehman-Breen, CO ;
Alpers, CE ;
Shankland, SJ .
KIDNEY INTERNATIONAL, 1999, 56 (05) :1691-1699
[2]
The lack of cyclin kinase inhibitor p27Kip1 ameliorates progression of diabetic nephropathy [J].
Awazu, M ;
Omori, S ;
Ishikura, K ;
Hida, M ;
Fujita, H .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (03) :699-708
[3]
Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies [J].
Barisoni, L ;
Mokrzycki, M ;
Sablay, L ;
Nagata, M ;
Yamase, H ;
Mundel, P .
KIDNEY INTERNATIONAL, 2000, 58 (01) :137-143
[4]
MECHANISMS OF PROGRESSIVE RENAL DISEASE IN GLOMERULONEPHRITIS [J].
COUSER, WG ;
JOHNSON, RJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1994, 23 (02) :193-198
[5]
Complement (C5b-9) induces DNA synthesis in rat mesangial cells in vitro [J].
Couser, WG ;
Pippin, JW ;
Shankland, SJ .
KIDNEY INTERNATIONAL, 2001, 59 (03) :905-912
[6]
Cell cycle checkpoints and their impact on anticancer therapeutic strategies [J].
Eastman, A .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2004, 91 (02) :223-231
[7]
Exogenous attenuation of p21Waf1/Cip1 decreases mesangial cell hypertrophy as a result of hyperglycemia and IGF-1 [J].
Fan, YP ;
Weiss, RH .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (03) :575-584
[8]
Activation of cyclin D1-Cdk4 and Cdk4-directed phosphorylation of RB protein in diabetic mesangial hypertrophy [J].
Féliers, D ;
Frank, MA ;
Riley, DJ .
DIABETES, 2002, 51 (11) :3290-3299
[9]
Cyclin-dependent kinase 5 is a regulator of podocyte differentiation, proliferation, and morphology [J].
Griffin, SV ;
Hiromura, K ;
Pippin, J ;
Petermann, AT ;
Blonski, MJ ;
Krofft, R ;
Takahashi, S ;
Kulkarni, AB ;
Shankland, SJ .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 165 (04) :1175-1185
[10]
Cell cycle control in glomerular disease [J].
Griffin, SV ;
Pichler, R ;
Dittrich, M ;
Durvasula, R ;
Shankland, SJ .
SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 2003, 24 (04) :441-457